Getting Lost in the Cell-Lysosomal Entrapment of Chemotherapeutics

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Dec 10

PMID 33297435

Citations 5

Authors

Xingjian Zhai

Yassine El Hiani

Affiliations

Soon will be listed here.

Abstract

Despite extensive research, resistance to chemotherapy still poses a major obstacle in clinical oncology. An exciting strategy to circumvent chemoresistance involves the identification and subsequent disruption of cellular processes that are aberrantly altered in oncogenic states. Upon chemotherapeutic challenges, lysosomes are deemed to be essential mediators that enable cellular adaptation to stress conditions. Therefore, lysosomes potentially hold the key to disarming the fundamental mechanisms of chemoresistance. This review explores modes of action of classical chemotherapeutic agents, adaptive response of the lysosomes to cell stress, and presents physiological and pharmacological insights pertaining to drug compartmentalization, sequestration, and extracellular clearance through the lens of lysosomes.

Citing Articles

Inflammasome activation in melanoma progression: the latest update concerning pathological role and therapeutic value.

Pluetrattanabha N, Direksunthorn T, Ahmad I, Jyothi S, Shit D, Singh A Arch Dermatol Res. 2025; 317(1):258.

PMID: 39820618 DOI: 10.1007/s00403-025-03802-1.

Chemo-small extracellular vesicles released in cisplatin-resistance ovarian cancer cells are regulated by the lysosomal function.

Cerda-Troncoso C, Grunenwald F, Arias-Munoz E, Cavieres V, Caceres-Verschae A, Hernandez S J Extracell Biol. 2024; 3(6):e157.

PMID: 38947172 PMC: 11212338. DOI: 10.1002/jex2.157.

Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights.

Lagzian A, Askari M, Haeri M, Sheikhi N, Banihashemi S, Nabi-Afjadi M Med Oncol. 2024; 41(5):108.

PMID: 38592406 DOI: 10.1007/s12032-024-02313-9.

Integrative proteomics and n-glycoproteomics reveal the synergistic anti-tumor effects of aspirin- and gemcitabine-based chemotherapy on pancreatic cancer cells.

Li X, Kong R, Hou W, Cao J, Zhang L, Qian X Cell Oncol (Dordr). 2023; 47(1):141-156.

PMID: 37639207 DOI: 10.1007/s13402-023-00856-z.

Drug Resistance and Novel Therapies in Cancers in 2020.

Wang Z Cancers (Basel). 2023; 15(3).

PMID: 36765674 PMC: 9913530. DOI: 10.3390/cancers15030717.

References

Salaroglio I, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman G . Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. J Exp Clin Cancer Res. 2018; 37(1):286. PMC: 6258159. DOI: 10.1186/s13046-018-0967-0. View

Wessel I, Jensen L, Jensen P, Falck J, Rose A, Roerth M . Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Res. 1999; 59(14):3442-50. View

Blatt J . Second malignancies associated with doxorubicin. Pediatr Hematol Oncol. 1995; 12(2):111-3. DOI: 10.3109/08880019509029542. View

Andrews N . Solving the secretory acid sphingomyelinase puzzle: Insights from lysosome-mediated parasite invasion and plasma membrane repair. Cell Microbiol. 2019; 21(11):e13065. PMC: 6842087. DOI: 10.1111/cmi.13065. View

Law F, Seo J, Wang Z, DeLeon J, Bolis Y, Brown A . The VPS34 PI3K negatively regulates RAB-5 during endosome maturation. J Cell Sci. 2017; 130(12):2007-2017. PMC: 5482978. DOI: 10.1242/jcs.194746. View

Derendorf H . Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Int J Antimicrob Agents. 2020; 55(6):106007. PMC: 7204663. DOI: 10.1016/j.ijantimicag.2020.106007. View

Zhitomirsky B, Yunaev A, Kreiserman R, Kaplan A, Stark M, Assaraf Y . Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity. Cell Death Dis. 2018; 9(12):1191. PMC: 6294013. DOI: 10.1038/s41419-018-1227-0. View

Harwood F, Geltink R, OHara B, Cardone M, Janke L, Finkelstein D . ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018; 4(9):eaar3938. PMC: 6156121. DOI: 10.1126/sciadv.aar3938. View

de Nully Brown P, Hoffmann T, Hansen O, Boesen A, Gronbaek K, Hippe E . Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III.... Leukemia. 1997; 11(1):37-41. DOI: 10.1038/sj.leu.2400514. View

10.

Miller M, Ojima I . Chemistry and chemical biology of taxane anticancer agents. Chem Rec. 2002; 1(3):195-211. DOI: 10.1002/tcr.1008. View

11.

Kaufmann S . Paul Ehrlich: founder of chemotherapy. Nat Rev Drug Discov. 2008; 7(5):373. DOI: 10.1038/nrd2582. View

12.

Khan Q, Pilch D . Topoisomerase I-mediated DNA cleavage induced by the minor groove-directed binding of bibenzimidazoles to a distal site. J Mol Biol. 2006; 365(3):561-9. PMC: 1849979. DOI: 10.1016/j.jmb.2006.10.032. View

13.

Aits S, Jaattela M . Lysosomal cell death at a glance. J Cell Sci. 2013; 126(Pt 9):1905-12. DOI: 10.1242/jcs.091181. View

14.

Gorvel J, Chavrier P, Zerial M, Gruenberg J . rab5 controls early endosome fusion in vitro. Cell. 1991; 64(5):915-25. DOI: 10.1016/0092-8674(91)90316-q. View

15.

Soll J, Sobol R, Mosammaparast N . Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities. Trends Biochem Sci. 2016; 42(3):206-218. PMC: 5336464. DOI: 10.1016/j.tibs.2016.10.001. View

16.

Rodriguez-Pascual J, Ayuso-Sacido A, Belda-Iniesta C . Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. Cancer Drug Resist. 2022; 2(4):980-993. PMC: 9019209. DOI: 10.20517/cdr.2019.61. View

17.

Goodman L, Wintrobe M, DAMESHEK W, GOODMAN M, Gilman A, McLennan M . Landmark article Sept. 21, 1946: Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous.... JAMA. 1984; 251(17):2255-61. DOI: 10.1001/jama.251.17.2255. View

18.

Azarenko O, Smiyun G, Mah J, Wilson L, Jordan M . Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells. Mol Cancer Ther. 2014; 13(8):2092-103. DOI: 10.1158/1535-7163.MCT-14-0265. View

19.

Pommier Y . DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009; 109(7):2894-902. PMC: 2707511. DOI: 10.1021/cr900097c. View

20.

Napolitano G, Di Malta C, Esposito A, de Araujo M, Pece S, Bertalot G . A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome. Nature. 2020; 585(7826):597-602. PMC: 7610377. DOI: 10.1038/s41586-020-2444-0. View